Business Context and Reporting Period
This Form 8-K Current Report was filed by PDS Biotechnology Corp on August 13, 2026, regarding events occurring on August 13, 2026, and August 19, 2026. The filing addresses significant changes in the company's executive leadership structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective September 12, 2026. The resignation is not the result of any disagreement with the company.
- Interim Appointments: On August 19, 2026, the Board appointed Janetta Trochimiuk (Controller) as interim Principal Accounting Officer and Frank Bedu-Addo, Ph.D. (President and CEO) as interim Principal Financial Officer, both effective September 12, 2026.
Management Commentary and Compensation
Ms. Trochimiuk will continue to receive her existing base salary of $279,519.57 per year and remains eligible for equity awards under the Company's Third Amended and Restated 2014 Equity Incentive Plan. No new equity awards were granted in connection with her promotion. The company confirmed there are no family relationships between Ms. Trochimiuk and other directors or officers, nor any undisclosed arrangements regarding her appointment.
Investor Verification Checklist
- Verify the effective date of the leadership transition (September 12, 2026).
- Confirm the qualifications and tenure of the interim Principal Accounting Officer, Janetta Trochimiuk.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Review upcoming financial reports to assess the impact of the leadership change on financial reporting processes.